Xtandi

Swallow whole. 160mg once daily until disease progression or unacceptable toxicity. CRPC or mCSPC: give concurrent GnRH analog or patient should have had bilateral orchiectomy. nmCSPC: may treat with or without a GnRH analog; can suspend treatment if PSA is undetectable (<0.2ng/mL) after 36 weeks; reinitiate treatment when PSA is ≥2.0ng/mL in those who had prior radical prostatectomy or ≥5.0ng/mL in those who had prior primary radiation therapy. Dose modifications: ≥Grade 3 toxicity or intolerable side effect: withhold dose for 1 week or until improvement to ≤Grade 2, then resume at same or reduced dose (120mg or 80mg), if warranted. Concomitant strong CYP2C8 inhibitors, if unavoidable: reduce to 80mg once daily. Concomitant strong CYP3A4 inducers, if unavoidable: increase to 240mg once daily. When CYP2C8 inhibitor or CYP3A4 inducer is discontinued, return enzalutamide dose to the dose used prior to initiation of the inhibitor or inducer.